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Abstract
Gefitinib (Iressa)–a specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase–has been shown to
suppress the activation of EGFR signaling required for cell survival and proliferation in non-small cell lung cancer (NSCLC)
cell lines. We recently provided novel evidence that gefitinib-sensitive PC9 cells show normal endocytosis of EGFR:
internalized EGF-EGFR complexes were transported to late endosomes/lysosomes 15 min after EGF stimulation, and
then degraded within the lysosomes. However, gefitinib-resistant QG56 cells showed internalized EGFR accumulation in
early endosomes after 60 min of internalization, instead of its trafficking to lysosomes, indicating an aberration in some
steps of EGF-EGFR trafficking from the early endosomes to late endosomes/lysosomes. Therefore, we postulate that
impairment in some steps of EGF-EGFR trafficking from early endosomes to late endosomes/lysosomes might confer
gefitinib-resistance in NSCLC cell lines. To further substantiate the detailed internalization mechanism of gefitinib-
sensitive and gefitinib-resistant cells, using confocal immunofluorescence microscopy, we examined the endocytic
trafficking of phosphorylated EGFR (pEGFR) in the absence or presence of gefitinib. In PC9 and QG56 cells without EGF
stimulation, a large number of pEGFR-positive small vesicular structures not colocalized with late endosomes/lysosomes
were spread throughout the cytoplasm, and some pEGFR staining was distributed in the nucleus. This implies a novel
intracellular trafficking pathway for pEGFR from cytoplasmic vesicles to the nucleus. Furthermore, an aggregated
vesicular structure of early endosomes was observed in the perinuclear region of QG56 cells; it was revealed to be
associated with SNX1, originally identified as a protein that interacts with EGFR. Therefore, we confirmed our previous
data that an aberration in some steps of EGF-EGFR trafficking from the early endosomes to late endosomes/lysosomes
occurs in QG56 cells. Furthermore, in PC9 cells, efficient phosphorylation of EGFR and rapid internalization of pEGFR
was observed at 3 min after EGF stimulation; these internalized pEGFR-positive vesicles were trafficked to late
endosomes at 15 min, indicating rapid trafficking of EGF-pEGFR complexes from early to late endosomes in PC9 cells.
Gefitinib treatment strongly reduced the phosphorylation level of EGFR, and subsequent endocytosis of EGFR was
significantly suppressed in PC9 cells. In contrast, in QG56 cells, EGFR trafficking via the early endocytic pathway was
basically impaired; therefore, gefitinib appeared to slightly suppress the internalization of pEGFR. Collectively, our data
provide novel evidence that extensive impairment in pEGFR endocytosis via the early endocytic pathway might confer
gefitinib-resistance in QG56 cells.
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Background
The epidermal growth factor receptor (EGFR) is a proto-
typical member of the ErbB family of tyrosine kinases and
plays an important role in the pathogenesis of different
tumors; therefore, therapies directed at inhibiting EGFR
function have potential as anticancer treatments [1,2].
Each EGFR comprises an extracellular binding domain
and a cytoplasmic domain with tyrosine kinase activity
[3]. Following ligand binding, the EGFR is dimerized and
the intracellular tyrosine kinase region is activated, caus-
ing receptor tyrosine autophosphorylation and transphos-
phorylation of another receptor monomer [4]. These
events lead to the recruitment and phosphorylation of
several intracellular substrates and the subsequent trans-
mission of extracellular signals to the nucleus via an intra-
cellular signaling network [4,5].
Gefitinib (Iressa, ZD1839) is a selective EGFR tyrosine
kinase inhibitor that functions by competing with ATP for
binding to the tyrosine kinase domain of the receptor, and
it blocks the signal transduction pathways implicated in
the proliferation and survival of cancer cells [6-9]. It has
exhibited significant antitumor activity against a broad
range of mouse tumor xenograft models in vivo [10] and
tumor cell lines in vitro [11]. A recent in vitro study dem-
onstrated that of the 9 non-small cell lung cancer
(NSCLC) cell lines examined, the PC9 cell line was most
sensitive to the effect of gefitinib when assayed under
basal growth conditions for EGFR phosphorylation and
activation of EGFR downstream effectors such as AKT and
those in the ERK1/2 pathway, which are required for its
survival and proliferation [11]. This suggests that the
mechanism underlying the sensitivity of the EGFR path-
way could be useful in predicting the potential effective-
ness of gefitinib in NSCLC patients. Inefficient EGFR
down regulation was observed in the gefitinib-resistant
cell line QG56, whereas rapid down regulation occurred
in the gefitinib-sensitive cell line PC9, wherein the cells
were in the exponential phase of growth, suggesting that a
different unknown down-regulation mechanism operates
in each cell type.
For many years, the endocytosis of EGFR has served as a
model for studying ligand-induced, receptor-mediated
endocytosis. On EGF stimulation, EGF-EGFR complexes
are internalized and transported via clathrin-coated vesi-
cles to early endosomes. EGFR then recruits and phospho-
rylates signaling molecules, leading to the activation of an
MAPK-signal transduction cascade–an important mecha-
nism for regulating cell growth [12]. Once delivered to the
lysosomes, EGF-EGFR complexes are degraded to cease
intracellular EGFR signaling via endocytosis; this process
is known as receptor down regulation. Therefore, endocy-
tosis of EGF-EGFR complex is closely related with attenu-
ation of intracellular EGFR signaling. With regard to the
effect of gefitinib on the EGFR down-regulation pathway,
we have recently examined the endocytosis of Texas red-
EGF in the absence or presence of gefitinib in both PC9
and QG56 cell lines, and then assessed the endocytic
pathway of internalized Texas red-EGF by using confocal
immunofluorescence microscopy [13]. We found novel
evidence that an aberration in some steps of EGF-EGFR
trafficking from the early endosomes to the late endo-
somes/lysosomes does occur in the gefitinib-resistant
human lung cancer cell line derived from NSCLC, whereas
endocytosis of EGFR is normal in gefitinib-sensitive PC9
cells [13], suggesting that impairment in some steps of
EGF-EGFR trafficking from early endosomes to late endo-
somes/lysosomes might confer gefitinib-resistance in
NSCLC cell lines.
Based on these phenomena, in order to further investigate
the relationship of EGFR signaling and EGFR endocytosis,
we have now used confocal immunofluorescence micros-
copy to substantiate the detailed mechanisms for endocy-
tosis of the ligand-induced activated form of EGFR, i.e.,
phosphorylated EGFR (pEGFR), via the early endosome/
late endosome/lysosome endocytic pathway in both
NSCLC cell lines, namely, the PC9 and QG56 cell lines.
Here, we report novel data regarding the occurrence of
rapid EGFR phosphorylation and endocytic delivery of
pEGFR from early endosomes to late endosomes/lyso-
somes in PC9 cells after EGF stimulation; however, endo-
cytosis of pEGFR is significantly perturbed via the early/
late endocytic pathway in QG56 cells.
Results
Intracellular distribution of pEGFR in gefitinib-sensitive or 
gefitinib-resistant NSCLC cell lines
In order to examine the intracellular distribution of
pEGFR in the gefitinib-sensitive NSCLC cell line PC9 or
the gefitinib-resistant cell line QG56, in the absence of
EGF stimulation, each cell line was double-labeled either
with antibodies specific to pEGFR or with those specific to
cathepsin D and lysosomal integral membrane pro-
tein(LIMPII) (Fig. 1). We determined the intracellular dis-
tribution of late endosomes/lysosomes by using
antibodies specific to lysosomal aspartic protease cathep-
sin D or LIMPII/lysosomal glycoprotein 85 (LGP85).
These proteins are distributed within endocytic organelles
and are at the highest concentration in the late endo-
somes/lysosomes, as observed for other lysosomal glyco-
proteins, namely, lysosomal associated membrane
protein-1 (LAMP-1) and LAMP-2 [14-17].
In PC9 cells (A), it is notable that most pEGFRs were local-
ized within small vesicular structures distributed through-
out the cytoplasm, and it is clear that some punctate
signals were found in the nucleus (a, d). The immunos-
taining pattern of pEGFR in QG56 cells (B) was similar toMolecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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Intracellular distribution of pEGFR in the NSCLC cell lines Figure 1
Intracellular distribution of pEGFR in the NSCLC cell lines. The gefitinib-sensitive NSCLC cell line, PC9 (A), or the 
gefitinib-resistant cell line, QG56 (B) was fixed and double-stained for LIMPII (red in b, h) or cathepsin D (red in e, k) and 
pEGFR (green) as described in the Materials section. Superimposed images of cathepsin D or LIMPII and pEGFR are shown in c, 
f, i, l. In both PC9 and QG56 cells, it is notable that pEGFR-positive small punctate vesicles are spreading in the cytoplasm and 
these vesicles are not colocalized with the LIMPII-, or cathepsin D-positive vesicular structures, and also pEGFR-positive punc-
tate stainings are clearly seen in the nucleus. Bar, 10 µm.Molecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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that in PC9 cells. Moreover, pEGFR staining was distrib-
uted in the cytosol and in the nucleus: some cytosolic
pEGFR was stained diffusely, while no staining was
observed in the plasma membrane (g, j). In both PC9 and
QG56 cells, the small pEGFR-positive vesicular structures
observed in large numbers were not costained with
LIMPII or the cathepsin D antibody (c, f, i, l). These results
indicate that pEGFR would be mainly distributed in the
cytoplasmic vesicles and possibly in early endosomes;
however, its distribution was also indicated in the nucleus
at the steady-state level without EGF stimulation.
Sorting nexin 1 (SNX1) is localized to the aggregated 
vesicular structures of early endocytic compartments in 
gefitinib-resistant NSCLC cells
It was reported previously that sorting nexin 1 (SNX1),
originally identified as a protein that interacts with EGFR
[18], is preferentially localized to early endosomes
through its phospholipid-binding motif termed the phox
homology (PX) domain [19]. It was also shown that over-
expression of SNX1 caused enhanced EGFR degradation
and that a deletion mutant of SNX1 blocked EGFR degra-
dation but failed to inhibit receptor endocytosis [18,20].
Therefore, it is suggested that SNX1 plays a role in endo-
some-lysosome trafficking.
In the present study, to investigate the intracellular distri-
bution of SNX1 with endocytosed transferrin–a marker of
early endosomes in NSCLC cell lines–PC9 or QG56 cells
were allowed to internalize Texas red-labeled transferrin
for 20 min. After transferrin binds to its receptor on the
cell surface, it is internalized via clathrin-coated vesicles
and is subsequently delivered to the early endosomes.
Confocal immunofluorescence microscopy studies
revealed that endogenous SNX1 was distributed primarily
to punctate vesicles and that it showed considerable over-
lap with endocytosed transferrin in the cytoplasm of PC9
cells (Fig. 2A, h). However, it was also shown that SNX1
staining did not overlap with late endosomes/lysosomes
labeled by the LIMPII antibody (Fig. 2A, d). In contrast,
SNX1 was distributed in the aggregated vesicular struc-
tures in the perinuclear region of QG56 cells, and SNX1
staining overlapped with Texas red-transferrin-positive
early endosomes (Fig. 2B, p). Interestingly, a part of
SNX1-positive aggregated vesicles were also colocalized
with late endosomes labeled with the LIMPII antibody
(Fig. 2B, l), therefore, indicating that membrane traffick-
ing of EGFR between early endosomes and late endo-
somes might be considerably suppressed in QG56 cells.
However, it was revealed to be normal in PC9 cells. Fur-
thermore, quantitative analysis was performed to deter-
mine the amounts of SNX1 that colocalized with LIMPII
(Fig. 2C) or with endocytosed Texas red-transferrin (Fig.
2D). These results confirm the presence of an aberration
in the early endosomes of QG56 cells.
Efficient phosphorylation of EGFR and rapid endocytosis 
of pEGFR via the early/late endocytic pathway in the 
gefitinib-sensitive NSCLC cell line
Receptor tyrosine kinases play important roles in cell
growth, survival, migration, and differentiation. Ligand-
induced activation of receptor tyrosine kinases leads to
the assembly of signaling protein complexes and subse-
quent activation of downstream signaling pathways [12].
The endocytosed receptors then undergo a sorting process
that determines the fate of the receptor and signal inten-
sity. These receptors are targeted to the lysosomes for deg-
radation–a process that terminates receptor signaling
[21].
In this study, we have substantiated the detailed mecha-
nisms for endocytosis of the ligand-induced activated
form of EGFR, i.e., pEGFR, via the early/late endocytic
pathway in both NSCLC cell lines, i.e., PC9 and QG56 cell
lines. To clarify EGFR internalization for each cell line, we
monitored the uptake of Texas red-conjugated EGF with
time. To minimize the involvement of recycling and/or
lysosomal degradation of the internalized EGFR, we
quantified Texas red-EGF uptake in each transfectant for
various time periods up to 15 min. The cells were incu-
bated with Texas red-EGF in the absence (A, C) or pres-
ence (B, D) of gefitinib at 37°C for 5, 10, and 15 min.
Confocal immunofluorescence microscopy was then used
to assess the distribution of internalized Texas red-EGF
and endocytosed vesicles stained with the anti-pEGFR
antibody (Fig. 3).
In the gefitinib-sensitive cell line PC9, efficient internali-
zation of pEGFR was observed after 5 min of internaliza-
tion, since large amounts of pEGFR staining was observed
to have colocalized with Texas red-EGF-positive small
endocytic vesicles, presumably early endosomes, in the
vicinity of the plasma membrane (a). Moreover, these ves-
icles costained with internalized pEGFR and Texas red-
EGF were maturated and distributed in the periphery of
the nucleus; they showed a gradual increase in size until
15 min of incubation (b, c). These pEGFR- and EGFR-cos-
tained vesicles are considered to be late endosomes/lyso-
somes. This therefore indicates rapid delivery of the
endocytosed EGF-EGFR complex from the early endo-
somes to the late endosomes, after EGF stimulation in
PC9 cells [13].
In contrast, in the gefitinib-resistant cell line QG56, inter-
nalization of Texas red-EGF was suppressed (Fig. 3C).
After 5 min of incubation, large amounts of pEGFR-posi-
tive vesicular structures were associated with the plasma
membrane, and internalization of Texas red-EGF was not
observed in the cell. Some pEGFR-positive vesicles over-
lapping with Texas red-EGF staining were revealed to have
accumulated as aggregated structures in the vicinity of theMolecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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Endocytosed Texas red-transferrin is downloaded into the SNX1-positive aggregated vesicular structure of early endosomes in  the perinuclear region of gefitinib-resistant QG56 cells Figure 2
Endocytosed Texas red-transferrin is downloaded into the SNX1-positive aggregated vesicular structure of early 
endosomes in the perinuclear region of gefitinib-resistant QG56 cells. The PC9 cells (A), or the QG56 cells (B) were 
fixed and double-stained for SNX1 (green in b, j) and LIMPII (red in c, k) as described in the Materials section. Superimposed 
images of SNX1 and LIMPII are shown in d, l. Each cell line was stained with DAPI (blue) to reveal nuclei. The merged confocal 
images as yellow color were quantified and presented as the percentage of total amounts of SNX1-positive vesicles per cell in C. 
The error bar denotes SD. In PC9 cells (A), SNX1-positive small vesicles are not colocalized with LIMPII-positive vesicles (d), 
however, in QG56 cells (B), part of LIMPII-positive vesicles colocalized with SNX1-positive early endosomes is seen in the peri-
nuclear region (l). Furthermore, superimposed images of SNX1 and the internalized Texas red-transferrin in the PC9 cells and 
the QG56 cells are shown in h and p, respectively. The merged confocal images as yellow color as indicated by white arrowheads 
(h) or white arrows (p) were quantified and presented as the percentage of total amounts of SNX1-positive vesicles per cell in D. 
Note that SNX1-positive early endosomes form large aggregated vesicular structures in the perinuclear region (p) in QG56 cells, 
and that these aggregated structures are overlapped with Texas red-transferrin; however no aggregated vesicles are seen in PC9 
cells (h).
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Evidence for a rapid endocytosis of ligand-induced pEGFR in the gefitinib-sensitive PC9 cells, but for an inefficient endocytic  traffic of EGF-pEGFR in the gefitinib-resisitant QG56 cells Figure 3
Evidence for a rapid endocytosis of ligand-induced pEGFR in the gefitinib-sensitive PC9 cells, but for an ineffi-
cient endocytic traffic of EGF-pEGFR in the gefitinib-resisitant QG56 cells. The PC9 (A, B) or QG56 (C, D) cells 
were incubated in the absence (A, C) or presence (B, D) of gefitinib at 37°C with Texas red-EGF for 5, 10, or 15 min, and cells 
were fixed and double-stained for pEGFR (green) as described in the Materials section. Superimposed images of pEGFR and 
Texas red-EGF are shown. The white arrowheads indicate the colocalization of the pEGFR-positive vesicles and Texas red-
EGF-positive vesicular structures. It is notable that rapid endocytosis of EGF-EGFR occurs in PC9 cells, since large amounts of 
pEGFR-positive small vesicles co-stained with Texas red-EGF appear in the cytoplasm after 5 min incubation (a) and these co-
stained vesicles are increased at 15 min (b, c). By contrast in QG 56 cells, pEGFR stainings are mostly associated with plasma 
membrane even after 15 min incubation (i). Further, gefitinib significantly suppresses phosphorylation of EGFR in NSCLC cell 
lines and amount of pEGFR stainings are considerably reduced during the incubation (d, e, f, j, k, l). Bar, 10 µm.Molecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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plasma membrane at 15 min of incubation (i). These data
indicate that EGF stimulation induces phosphorylation of
EGFR in the plasma membrane of QG56 cells; however,
internalization of the pEGFR-EGF complex from the
plasma membrane to endocytic vacuoles is fairly sup-
pressed in this cell line. This is consistent with our previ-
ously reported novel evidence that in QG56 cells, the
endocytic machinery of EGFR is basically impaired at the
level of the early endocytic pathway [13].
Gefitinib is an active EGFR tyrosine kinase inhibitor that
competes for the ATP-binding site in the cytoplasmic tail,
thus inhibiting EGFR activation and the transduction of
post-receptor signaling pathways. Using confocal immun-
ofluorescence microscopy, we have recently demonstrated
that in PC9 cells, gefitinib significantly inhibited the effi-
cient internalization rate of Texas red-EGF in the early
stage of endocytosis, from the plasma membrane to the
early endosomes; furthermore, it was also indicated that
the suppressive effect of gefitinib on the endocytosis of
EGFR proved to be much stronger in PC9 cells than in
QG56 cells [13].
In the present study, to further substantiate the effect of
gefitinib on the EGFR down-regulation pathway and to
understand the internalization mechanism of PC9 cells or
QG56 cells in detail, we examined the effect of gefitinib
on the phosphorylation of EGFR and the subsequent
internalization of pEGFR in the presence of gefitinib in
each cell line for various time periods upto 15 min. Con-
focal immunofluorescence microscopy was used to assess
the distribution of internalized Texas red-EGF and intrac-
ellular vesicles stained with the anti-pEGFR antibody. The
results revealed that the gefitinib treatment strongly
reduced the phosphorylation level of EGFR and that the
endocytosis of EGFR was significantly suppressed in PC9
cells (Fig. 3B). Ever after 15 min of internalization, most
of the Texas red-EGF remained associated with the plasma
membrane of gefitinib-treated PC9 cells instead of being
trafficked to the early endosomes (Fig. 3B, f). Similarly,
the suppression of EGFR phosphorylation was observed
in QG56 cells; in most of the Texas red-EGF-stained cells,
no internalization of Texas red-EGF staining was observed
even after 15 min of incubation, since it remained
attached to the plasma membrane (Fig. 3D, l). These
results indicate that in PC9 cells, gefitinib significantly
inhibits the efficient phosphorylation of EGFR and rapid
internalization of pEGFR in the early stage of endocytosis,
from the plasma membrane to the early endosomes. Fur-
ther, the suppressive effect of gefitinib on the endocytosis
of pEGFR proved to be much stronger in PC9 cells than in
QG56 cells, since pEGFR trafficking via the early endocytic
pathway is basically perturbed in QG56 cells; however,
the pEGFR endocytic pathway is normal in PC9 cells.
Phosphorylated EGFR is rapidly endocytosed and 
trafficked to late endosomes/lysosomes in gefitinib-
sensitive cell lines
To clarify pEGFR internalization, confluent NSCLC cell
lines were cultured in serum-free medium for 3 h, and
then EGFR phosphorylation was induced by incubation
with EGF (100 ng/ml) for 15 min on ice in a binding
medium (1 mg/ml bovine serum albumin (BSA) in RPMI
medium). The cells were then rinsed with ice-cold phos-
phate-buffered saline (PBS), incubated in the presence of
Texas red-transferrin in a prewarmed medium, and chased
at 37°C for 3, 6, and 15 min.
Using confocal immunofluorescence microscopy, we then
assessed the intracellular distribution of pEGFR and inter-
nalized Texas red-transferrin, an endocytic marker (Fig.
4). We previously reported that in NSCLC cell lines or in
human breast cancer cell lines, internalized transferrin is
predominantly distributed in the form of small punctate
structures in the perinuclear and peripheral regions, pre-
sumably representing recycling endosomes and sorting
endosomes, respectively [13,22-24]. The gefitinib-sensi-
tive cell line PC9 showed rapid internalization of pEGFR
since pEGFR-positive vesicular structures were observed in
the cell at 3 min of internalization; moreover, these
pEGFR-positive vesicles were colocalized with transferrin
receptor-positive early endosomes (Fig. 4A, a), indicating
rapid phosphorylation of EGFR and its efficient delivery
to early endosomes after EGF stimulation. After 15 min of
internalization, an increasing number of pEGFR-positive
vesicular structures costained with endocytosed Texas red-
transferrin was observed in the vicinity of the nucleus (Fig.
4A, c).
In contrast, in the gefitinib-resistant cell line QG56, inter-
nalization of pEGFR was suppressed (Fig. 4B). Even after
15 min of internalization, only a small number of pEGFR-
positive vesicles associated with the internalized Texas
red-transferrin staining were observed in the perinuclear
region of QG56 cells (Fig. 4B, f). These data indicate that
in QG56 cells, an aberration in pEGFR endocytosis occurs
via the early/late endocytic pathway and the delivery of
pEGFR from the early endosomes to late endosomes/lys-
osomes is also considerably perturbed. Quantitative anal-
ysis was performed to determine the amount of Texas red-
transferrin-positive early endosomal markers (Fig. 4C)
that colocalized with the endocytosed pEGFR at 3 min of
internalization; it was confirmed that rapid delivery of
pEGFR to early endosomes is observed to a greater extent
in PC9 cells than in QG56 cells.
To further examine pEGFR internalization, using confocal
immunofluorescence microscopy, the intracellular fate of
pEGFR that colocalized with the late endosome/lysosome
marker stained with the LIMPII antibody was monitoredMolecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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Evidence for an efficient phosphorylation of EGFR and rapid delivery of pEGFR into the early endosomes after EGF stimulation  in PC9 cells Figure 4
Evidence for an efficient phosphorylation of EGFR and rapid delivery of pEGFR into the early endosomes after 
EGF stimulation in PC9 cells. The PC9 (A) or QG56 (B) cells stimulated with EGF for 15 min on ice were further incu-
bated at 37°C with Texas red-transferrin (red) for 3, 6, or 15 min, and cells were fixed and double-stained for pEGFR (green) 
as described in the Materials section. Superimposed images of pEGFR and Texas red-transferrin are shown. Each cell line was 
stained with DAPI (blue) to reveal nuclei. The white arrows indicate the colocalized early endosomal vesicular structures pos-
itive for pEGFR and Texas red-transferrin. The merged confocal images as yellow color as indicated by white arrows (a, d) at 3 
min incubation were quantified and presented as the percentage of total amounts of pEGFR-positive vesicles per cell in D. In 
PC9 cells (A), ligand-induced EGFR phosphorylation occurs efficiently in early endosomes or in plasma membrane (a, b, c). By 
contrast, only small fraction of pEGFR staining associated with early endosomal vesicles is seen in the cytoplasm of QG56 cells 
even after 15 min incubation (f).
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for various time periods upto 15 min by using each cell
line. As shown in Fig. 5A, in PC9 cells, an increasing
number of pEGFR-positive vesicles colocalized with
LIMPII-positive late endosomes/lysosomes were observed
in the cytoplasm at 15 min of internalization (Fig. 5A, c);
however, in QG56 cells, no pEGFR-positive vesicular
structures overlapping with LIMPII-positive late endo-
somes/lysosomes were observed (Fig. 5A, d). We have pre-
viously reported that the EGF-EGFR complex associated
with the plasma membrane is efficiently endocytosed and
translocated to LIMPII-positive late endosomes/lyso-
somes at 15 min after EGF stimulation in PC9 cells  [13];
therefore, our present data showing the efficient traffick-
ing of pEGFR from the plasma membrane via early endo-
somes to late endosomes within 15 min of EGF
stimulation is consistent with that reported previously.
These results further confirm that ligand-induced pEGFR
endocytosis operates normally in PC9 cells, but pEGFR
trafficking is attenuated at the level of the early endocytic
pathway in QG56 cells. Quantitative analysis for deter-
mining the amounts of LIMPII-positive late endosome/
lysosome markers (Fig. 5B) that colocalized with the
endocytosed pEGFR at 15 min of internalization con-
firmed the efficient trafficking of pEGFR to late endo-
somes in PC9 cells and attenuation of endocytic vesicular
trafficking in QG56 cells.
Discussion
In the present study, using confocal immunofluorescence
microscopy, we demonstrated that in PC9 cells, efficient
phosphorylation of EGFR and rapid internalization of
pEGFR occurred at 3 min after EGF stimulation, since
large amounts of small pEGFR-positive punctate vesicles
were colocalized with the internalized Texas red-transfer-
rin-positive early endosomes in the vicinity of the plasma
membrane. These internalized pEGFR-positive vesicles
were maturated and subsequently trafficked to LIMPII-
positive late endosomes/lysosomes in the periphery of
nucleus, along with gradual increases in its size at 15 min
after EGF stimulation. These results indicate that efficient
membrane trafficking of the EGF-pEGFR complex from
early endosomes to late endosomes occurs in PC9 cells,
and also suggest that ligand-induced EGFR signaling
might operate in the early endosomes/late endosomes via
the endocytic pathway. Furthermore, in the gefitinib-
treated PC9 cells, endocytic trafficking of EGFR was signif-
icantly impaired and unphosphorylated EGFR remained
associated with the plasma membrane. Therefore, the sup-
pressive effect of gefitinib on the phosphorylation level of
EGFR was demonstrated. In contrast, internalization of
pEGFR was basically suppressed in QG56 cells; therefore,
the inhibitory effect of gefitinib on pEGFR trafficking is
limited. Collectively, our data indicate that an aberration
in pEGFR endocytosis occurs via the early/late endocytic
pathway and that the delivery of pEGFR from the early
endosomes to the late endosomes/ysosomes is considera-
bly perturbed in QG56 cells. Based on these findings, we
postulate that efficient endocytosis of ligand-induced
EGFR is closely related to EGFR-tyrosine kinase inhibitor
sensitivity of human lung cancer cell lines.
We further detected clear nuclear staining of pEGFR in
PC9 and QG56 cells, although considerable amounts of
pEGFR were distributed in small cytoplasmic punctate
vesicles. Since we recently demonstrated that in PC9 cells,
most EGFR is localized in the plasma membrane and in
LIMPII-positive swollen vacuoles, i.e., late endosomes
[13], it is interesting to note that a part of pEGFR is already
localized in the nucleus even in the absence of EGF stim-
ulation. These results imply that pEGFR might be translo-
cated into the nucleus through the conventional nuclear
importing system associated with the nuclear pore com-
plex (that is, the Ran/importin pathway), and it might
then operate as a transcription factor. In fact, it has
recently been reported that nuclear localization of EGFR is
detected in the highly proliferating state of human cancer
tissues in vivo and human breast cancer cell lines in vitro,
supporting the close correlation between nuclear EGFR
and tumor tissues with high proliferation [25-27]. It was
also shown that nuclear EGFR levels were increased on
treatment with EGF and that the EGFR which accumu-
lated in the nucleus was highly tyrosine phosphorylated;
it was further demonstrated that nuclear EGFR acts as a
transcription factor for activating gene expression of cyclin
D1, a well-known cell growth-promoting factor [26].
Therefore, further studies with respect to the functions of
these cell growth nuclear receptors should be conducted
to create new avenues in the field of receptor signaling.
With regard to the endocytosis of EGFR via the early endo-
cytic pathway in gefitinib-resistant cell lines, for QG56
cells, we reported novel evidence regarding the accumula-
tion of internalized EGF-EGFR in the early endosomes,
instead of its trafficking to the lysosomes; this evidence
suggests that the endocytic machinery of EGFR might be
considerably impaired at the level of the early/late endo-
somes [13]. To further substantiate this, we examined the
intracellular distribution of SNX1 along with endocytosed
transferrin in NSCLC cell lines. SNX1 is a mammalian
homologue of yeast Vps5p, which recognizes the lyso-
somal targeting code of EGFR and participates in lyso-
somal trafficking of the receptor [18,28]; SNX1 is
preferentially localized to early endosomes through its
phospholipid-binding motif termed the PX domain [19].
In the present study, using confocal immunofluorescence
microscopy, we demonstrated novel evidence that in
QG56 cells, early endosomes labeled with endocytosed
Texas red-transferrin formed an aggregated vesicular struc-
ture distributed in the perinuclear region and SNX1 distri-
bution overlapped with these aggregated early endosomalMolecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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Identification for an efficient pEGFR trafficking via early/late endocytic pathway in PC9 cells Figure 5
Identification for an efficient pEGFR trafficking via early/late endocytic pathway in PC9 cells. The PC9 or QG56 
cells were preincubated with EGF for 15 min on ice and then cell were chased at 37°C for 3, 6, or 15 min, and cells were fixed 
and double-stained for pEGFR (green) or LIMPII (red) as described in the Materials section. Superimposed images of pEGFR 
and LIMPII are shown. Each cell line was stained with DAPI (blue) to reveal nuclei. The white arrows indicate the colocalized 
LIMPII-positive late endosomes/lysosomes and pEGFR-positive cytoplasmic vesicular structures. The merged confocal images 
as yellow color as indicated by white arrows (c, d) at 15 min incubation were quantified and presented as the percentage of 
total amounts of LIMPII-positive vesicles per cell in B. It is notable that an efficient trafficking of pEGFR to late endosomes is 
seen in PC9 cells (a, b, c), but is not observed in QG56 cells (d).
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vesicles. Surprisingly, a part of SNX1-positive aggregates
was also colocalized with late endosomes labeled with the
LIMPII antibody, implying that membrane trafficking of
EGFR from the early endosomes to late endosomes might
be significantly impaired in QG56 cells; however, no such
accumulation was noted in PC9 cells. Therefore, we spec-
ulate that impairment of SNX1 trafficking might cause the
perturbation of EGFR endocytosis, which then leads to the
acquisition of gefitinib-resistance in NSCLC cell lines.
It has been previously reported that gefitinib-sensitive
lung tumors were found to express EGFR variants with a
higher sensitivity for the drug than the wild-type receptor
[29,30]. Since it has been known that PC9 cells express
EGFR mutant variants and QG56 cells express wild-type
EGFR [11], it can be assumed that the drug suppresses the
endocytosis of EGFR more strongly in gefitinib-sensitive
PC9 cells than in gefitinib-resistant QG56 cells. Recently,
cellular targets of gefitinib were identified in HeLa cells by
a proteomic method in which gefitinib could interact with
more than 20 previously unknown kinase targets [31].
They further found novel evidence that gefitinib could
interact with the serine/threonine kinase, cyclin G-associ-
ated kinase (GAK), which has been recently indicated to
act as a negative regulator of EGFR signaling [32], thereby
proposing that the gefitinib-mediated inactivation of a
negative regulator would antagonize the inhibitory effect
of the drug on EGFR signaling. It is important to further
analyze the mechanism by which the interaction of EGFR
and other cellular proteins with gefitinib might regulate
the process of EGFR down regulation in NSCLC cell lines.
Further analysis of the endocytosis machinery in gefitinib-
sensitive or gefitinib-resistant NSCLC cell lines could be
useful for clarifying the effectiveness of gefitinib.
Conclusion
We found novel evidence for efficient EGFR phosphoryla-
tion and rapid endocytic delivery of pEGFR from plasma
membrane to early endosomes/late endosomes/lyso-
somes in the gefitinib-sensitive cell line PC9 cells after
EGF stimulation; however, pEGFR trafficking via the early
endocytic pathway was basically impaired in the gefitinib-
resistant cell line QG56 cells, since internalized pEGFR
was accumulated in the aggregated vesicular structures of
early endosomes associated with SNX1 instead of its traf-
ficking to late endosomes/lysosomes. Therefore, we sug-
gest that extensive impairment in pEGFR endocytosis via
the early endocytic pathway might confer gefitinib-resist-
ance in QG56 cells. Thus impairment of protein function
such as SNX1 regulating EGFR trafficking in the early
endocytic pathway might cause the perturbation of EGFR
endocytosis, which then leads to the acquisition of gefit-
inib-resistance in NSCLC cell lines.
Methods
Materials
Gefitinib was provided from AstraZeneca (Macclesfield,
United Kingdom). Texas red-labeled transferrin, Texas
red-labeled EGF, and SlowFade anti-fade reagent were
purchased from Molecular Probes (Eugene, OR, USA).
DAPI was obtained from Sigma (St. Louis, MO, USA).
Recombinant human EGF was purchased from PeproTech
(London, United Kingdom). Other chemicals were of rea-
gent grade and were obtained from commercial sources.
Cell culture
Cell lines PC9 and QG56 (Kyushu Cancer Center, Fuku-
oka, Japan) were cultured in RPMI supplemented with
10% fetal bovine serum (FBS). Cells were maintained
under standard cell culture conditions at 37°C and 5%
CO2 in a humid environment.
Antibodies
Alexa 488-labeled goat anti-mouse and goat anti-rabbit
secondary antibodies, Texas red-labeled human transfer-
rin, and Texas red-labeled EGF were obtained from Molec-
ular Probes (Eugene, OR, USA). Normal goat serum was
purchased from Sigma (St. Louis, MO, USA). Antisera
were raised in rabbits (New Zealand white male) against
the mature form of rat liver lysosomal cathepsin D [33,34]
and the native form of LIMPII/LGP85 [15] as described
previously. Anti-cathepsin D or anti-LIMPII IgG was affin-
ity-purified by protein A Sepharose CL-4B (Sigma), fol-
lowed by immunoaffinity chromatography using antigen-
conjugated Sepharose 4B. A mouse monoclonal anti-
pEGFR was obtained from DakoCytomation (Denmark)
and BD Biosciences (San Jose, CA, USA). Mouse mono-
clonal antibody to SNX1 was purchased from BD Bio-
sciences (San Jose, CA, USA).
Immunofluorescence microscopy
Immunofluorescence microscopy was described previ-
ously [13,22-24]. In brief, cells were grown for 2 days on
glass coverslips in 6-well plates in RPMI with 10% fetal
bovine serum. Cells were fixed with 3.7% formaldehyde
in phosphate-buffered saline (PBS), pH 7.4, permeabi-
lized in PBS containing 0.1% saponin. After washing with
PBS, cells were blocked with PBS-10% normal goat serum.
All subsequent antibody and wash solutions contained
0.1% saponin. The PC9 or QG56 cells were incubated
with specific primary antibodies (rabbit anti-cathepsin D
and anti-LIMPII IgGs, mouse anti-pEGFR mAb, or mouse
anti-SNX1 mAb), for 1 h, followed by washes with PBS
containing 0.1% saponin and incubation for 1 h with the
secondary antibodies at 20 µg/ml. Each cell line was
stained with DAPI to reveal nuclei. To label early endo-
somes, cells were incubated with RPMI without FBS for 3
h at 37°C followed by 20 min incubation in culture
medium containing Texas red-conjugated transferrin, andMolecular Cancer 2008, 7:42 http://www.molecular-cancer.com/content/7/1/42
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then cells were fixed and stained for SNX1. Controls for
antibody specificity were either preimmune serum (rabbit
or mouse) or omission of the primary antibodies. To fol-
low the endocytic pathway and determine the intracellu-
lar fate of internalized labeled ligand, the uptake of Texas
red-conjugated-EGF by the cells was measured. The PC9
or QG56 cells were starved for 3 h with RPMI without FBS
at 37°C. The serum-starved cells were preincubated for 3
h in the absence or presence of 0.1 µM gefitinib before
incubation with Texas red-EGF (100 ng/ml) at 37°C for 5,
10, and 15 min, and then the cells were fixed and stained
for pEGFR. The distribution of the labeled proteins was
analyzed by confocal immunofluorescence microscopy of
the fixed cells. In some cases, PC9 or QG56 cells were
starved for 3 h with RPMI without FBS at 37°C and then
the phosphorylation of the EGFR was induced with EGF
(100 ng/ml) for 15 min on ice in binding medium (1 mg/
ml BSA in RPMI medium). The cell were then rinsed with
ice-cold PBS, incubated in the presence of Texas red-trans-
ferrin in prewarmed medium, and chased at 37°C for 3, 6,
and 15 min. Slides were mounted with SlowFade anti-
fade reagent and observed on a Zeiss LSM 510 META con-
focal laser scanning microscope (Carl Zeiss, Oberkochen,
Germany), equipped with krypton/argon laser sources.
For quantification of colocalization between Texas red-
EGF and pEGFR, between Texas red-transferrin and SNX1,
between Texas red-transferrin and pEGFR, or between
LIMPII and pEGFR, merged images as yellow color were
quantified and presented as the percentage of total
amounts of SNX1-, pEGFR- or LIMPII-positive vesicles per
cell.
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